TP 2021
Alternative Names: JT-09; JT-09 Implant; JT-09 ProNeura implants; TP-2021Latest Information Update: 20 May 2025
At a glance
- Originator JT Pharmaceuticals
- Developer JT Pharmaceuticals; Medical University of South Carolina
- Class Analgesics; Antipruritics; Peptides; Skin disorder therapies
- Mechanism of Action Opioid kappa receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Pruritus
- Preclinical Pain
Most Recent Events
- 20 May 2025 TP 2021 is still in preclinical trials for Pain (PO) and Pruritus (SC) in USA (Titan Pharmaceuticals pipeline, May 2025)
- 20 May 2025 Phase-I clinical trials in Pruritus in USA (SC) (Titan Pharmaceuticals pipeline, May 2025)
- 19 Apr 2023 TP 2021 is available for licensing as of 19 Apr 2023. https://ir.titanpharm.com/